Literature DB >> 28540033

Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain.

Álvaro López-Díaz1, José Luis Fernández-González1, José Evaristo Luján-Jiménez1, Sara Galiano-Rus1, Luis Gutiérrez-Rojas1.   

Abstract

The rapidly-acting antidepressant properties of ketamine are a trend topic in psychiatry. Despite its robust effects, these are ephemeral and can lead to certain adverse events. For this reason, there is still a general concern around the off-label use of ketamine in clinical practice settings. Nonetheless, for refractory depression, it should be an indication to consider. We report the case of a female patient admitted for several months due to a treatment-resistant depressive bipolar episode with chronic suicidal behaviour. After repeated intravenous ketamine infusions without remarkable side effects, the patient experienced a complete clinical recovery during the 4 weeks following hospital discharge. Unfortunately, depressive symptoms reappeared in the 5th week, and the patient was finally readmitted to hospital as a result of a suicide attempt.

Entities:  

Keywords:  antidepressive agents; bipolar disorder; depression; ketamine; suicide

Year:  2017        PMID: 28540033      PMCID: PMC5433615          DOI: 10.1177/2045125316675578

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  27 in total

1.  Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.

Authors:  Mark A Frye; Pierre Blier; Susannah J Tye
Journal:  J Clin Psychopharmacol       Date:  2015-06       Impact factor: 3.153

2.  Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.

Authors:  Nick Ford; Guy Ludbrook; Cherrie Galletly
Journal:  Aust N Z J Psychiatry       Date:  2015-06-09       Impact factor: 5.744

3.  [Effect of sub-anaesthetic doses of ketamine in the postoperative period in a patient with uncontrolled depression].

Authors:  M Cortiñas-Saenz; M B Alonso-Menoyo; C L Errando-Oyonarte; I Alférez-García; M A Carricondo-Martínez
Journal:  Rev Esp Anestesiol Reanim       Date:  2012-07-19

4.  Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.

Authors:  Cristina Cusin; Dawn Flosnik Ionescu; Kara Jean Pavone; Oluwaseun Akeju; Paolo Cassano; Norman Taylor; Matthias Eikermann; Kelley Durham; Michaela Ballentyne Swee; Trina Chang; Christina Dording; David Soskin; John Kelley; David Mischoulon; Emery Neal Brown; Maurizio Fava
Journal:  Aust N Z J Psychiatry       Date:  2017-01       Impact factor: 5.744

5.  Serial infusions of low-dose ketamine for major depression.

Authors:  Keith G Rasmussen; Timothy W Lineberry; Christine W Galardy; Simon Kung; Maria I Lapid; Brian A Palmer; Matthew J Ritter; Kathryn M Schak; Christopher L Sola; Allison J Hanson; Mark A Frye
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

6.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

Review 7.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.

Authors:  A McGirr; M T Berlim; D J Bond; M P Fleck; L N Yatham; R W Lam
Journal:  Psychol Med       Date:  2014-07-10       Impact factor: 7.723

Review 8.  Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy.

Authors:  Caroline Caddy; Giovanni Giaroli; Thomas P White; Sukhwinder S Shergill; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-04

9.  Robust and sustained effect of ketamine infusions coadministered with conventional antidepressants in a patient with refractory major depression.

Authors:  José Manuel Montes; Elena Luján; Fernado Pascual; Jose María Beleña; Jose Luis Perez-Santar; Luis Javier Irastorza; Jerónimo Saiz-Ruiz
Journal:  Case Rep Psychiatry       Date:  2015-03-04

10.  Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

Authors:  Peter R Diamond; Andrew D Farmery; Stephanie Atkinson; Jag Haldar; Nicola Williams; Phil J Cowen; John R Geddes; Rupert McShane
Journal:  J Psychopharmacol       Date:  2014-04-03       Impact factor: 4.153

View more
  8 in total

1.  Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.

Authors:  Gilmar Gutierrez; Joshua Rosenblat; Emily Hawken; Jennifer Swainson; Gustavo Vazquez
Journal:  JMIR Res Protoc       Date:  2022-05-23

2.  Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.

Authors:  Mark Sinyor; Marissa Williams; Sue Belo; Beverley Orser; Margaret Vincent; Linda Mah; Carlos Zarate; Saulo Castel; Anthony J Levitt; Ayal Schaffer
Journal:  J Affect Disord       Date:  2018-07-29       Impact factor: 4.839

3.  Infusing hope into the treatment of suicidality: A review of ketamine's effects on suicidality.

Authors:  Manivel Rengasamy; Kimberly Hsiung; Rebecca B Price
Journal:  Curr Behav Neurosci Rep       Date:  2019-12-02

4.  The effects of ketamine on suicidality across various formulations and study settings.

Authors:  David Dadiomov; Kelly Lee
Journal:  Ment Health Clin       Date:  2019-01-04

5.  Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression.

Authors:  Marcos Gómez-Revuelta; María Fernández-Rodríguez; Laura Boada-Antón; Javier Vázquez-Bourgon
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-23

6.  Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.

Authors:  Chuanjun Zhuo; Feng Ji; Hongjun Tian; Lina Wang; Feng Jia; Deguo Jiang; Ce Chen; Chunhua Zhou; Xiaodong Lin; Jingjing Zhu
Journal:  Brain Behav       Date:  2020-07-03       Impact factor: 2.708

7.  Ketamine for Bipolar Depression: A Systematic Review.

Authors:  Anees Bahji; Carlos A Zarate; Gustavo H Vazquez
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

8.  Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.

Authors:  Jolien K E Veraart; Sanne Y Smith-Apeldoorn; Iris M Bakker; Berber A E Visser; Jeanine Kamphuis; Robert A Schoevers; Daan J Touw
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.